Navigation Links
URMC clinical trial tests new regimen for hypertension
Date:4/26/2012

Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.

The study drug, carvedilol (brand name Coreg), is FDA approved and widely used for the treatment of high blood pressure. What researchers hope to learn is how varying amounts of the medication, including doses lower than typically prescribed, affect patients with mild or stage 1 hypertension a systolic pressure (top number) ranging from 140 to 160 mm Hg.

According to hypertension expert and study investigator John D. Bisognano, M.D., Ph.D., people with this early form of the disease are often advised to try lifestyle changes, such as eating a healthier diet and exercising, for six months to a year before initiating drug therapy. For individuals implementing lifestyle modifications who are also considering medical treatment, the trial provides an opportunity to try a safe and effective drug that, even at varying doses, may help bring their blood pressure back to healthy levels.

"It is so ingrained in everyone's mind that we have to have a constant level of medication, but it is possible that if the drug level goes down, the brain may be able to make up for that," said Bisognano, director of Cardiology Outpatient Services who will run the trial with Francisco A. Tausk, M.D., professor in the Departments of Dermatology and Psychiatry and Jan A. Moynihan, Ph.D., Engel Professor in Psychosocial Medicine also in the Department of Psychiatry at the Medical Center. "We may be able to meet the medical need with less medication in this low-risk population and potentially decrease side effects in the process."

Such an outcome would be a huge step forward for the millions of Americans with mild hypertension who are limited in the amount or number of medications that they can take because of adverse side effects. It may also appeal to the growing number of Americans who are skeptical of or want to avoid standard pharmaceuticals, a culture change that Bisognano and other physicians have witnessed in their practices over the past few years.

According to the Centers for Disease Control and Prevention, nearly a third of the nation's adults struggle with high blood pressure, which increases the risk of heart disease and stroke and represents a significant economic burden to society, with $54 billion spent on the condition in 2001 alone.

People with mild hypertension who pass a medical exam may be eligible for the study. Once enrolled, individuals will receive different daily amounts of the study drug for at least three and up to eight weeks. In addition to brief weekly visits, participants will be asked to: monitor their blood pressure every morning and evening; record their results and any side effects in a blood pressure diary; and fill out weekly questionnaires regarding how they feel and any noteworthy events or changes that took place.

Individuals who complete study weeks one through three will be paid $100, and those who go on to complete weeks four through eight will be paid another $100. All travel expenses for appointments will also be reimbursed.


'/>"/>
Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Stethoscope App gives iPhone New Clinical Skills
2. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
3. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
4. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
5. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
6. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
7. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
8. TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux
9. Mesothelioma Clinical Trials List Offered by IQ Mesothelioma: Search Current Mesothelioma Treatment Options
10. MedQuist Launches EHR Integration for Dictations Associated with Template-based Clinical Documentation
11. Greenway Medical Technologies Donates Electronic Health Record, Clinical Research and Revenue Cycle Solutions to Northern Kentucky University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA Training ... Institute Education Center headquartered in Northern California, has issued an important reminder to ... their worksites. Employers with workers exposed to high temperatures should establish a ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ePAY ... partnership with Connance, a healthcare industry leader providing predictive analytics to optimize ... combine to provide health systems, hospitals and ambulatory surgical centers with dramatic ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) ... measures required to build a strong and stable market ... listed on the OTC Markets-pink current trading platform. ... "We are seeing an anomaly in market trading activities ... by the Company, but shareholders and market players as ...
Breaking Medicine Technology: